MeiraGTx News Releases https://investors.meiragtx.com/ MeiraGTx News Releases en MeiraGTx Reports First Quarter 2019 Financial Results and Provides Corporate Update https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-reports-first-quarter-2019-financial-results-and • Positive 6-month results from Phase 1/2 clinical trial of AAV-RPE65 • Enrollment completed in the Phase 1/2 clinical trial investigating AAV-CNGB3 gene therapy for the treatment of achromatopsia LONDON and NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a Tue, 14 May 2019 08:00:00 -0400 MeiraGTx News Releases 7026 MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiency https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-announces-positive-6-month-data-phase-12-trial AAV-RPE65 met the primary endpoint of safety and tolerability Statistically significant improvement demonstrated in vision-guided mobility and visual function in treated eyes compared to untreated eyes Dose selected for pivotal study; Company expects to meet with global regulatory authorities in Tue, 14 May 2019 07:30:00 -0400 MeiraGTx News Releases 7021 MeiraGTx Appoints Nicole Seligman to Board of Directors https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-appoints-nicole-seligman-board-directors LONDON and NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Nicole Seligman to its Board of Directors. Ms. Seligman is an accomplished leader with extensive executive, Fri, 10 May 2019 08:30:00 -0400 MeiraGTx News Releases 6996 MeiraGTx to Present at Bank of America Merrill Lynch Healthcare Conference https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-present-bank-america-merrill-lynch-healthcare LONDON and NEW YORK , May 06, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc  (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the BAML Healthcare Mon, 06 May 2019 16:30:00 -0400 MeiraGTx News Releases 6986 MeiraGTx Announces Upcoming Presentation on Achromatopsia Gene Therapy Candidate AAV-CNGA3 at ARVO 2019 https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-announces-upcoming-presentation-achromatopsia-gene LONDON and NEW YORK , April 25, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced a pre-clinical poster on safety and efficacy of the Company’s gene therapy product candidate AAV-CNGA3 for the treatment of Thu, 25 Apr 2019 16:30:00 -0400 MeiraGTx News Releases 6961 MeiraGTx Reports Full Year 2018 Financial Results https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-reports-full-year-2018-financial-results LONDON and NEW YORK, March 26, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the fourth quarter and full year ended December 31, 2018 . “2018 was a transformative year for MeiraGTx Tue, 26 Mar 2019 16:05:00 -0400 MeiraGTx News Releases 6926 MeiraGTx to Present at the Barclays Global Healthcare Conference https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-present-barclays-global-healthcare-conference LONDON and NEW YORK, March 06, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes , Ph.D., president and chief executive officer, will present at the Barclays Global Healthcare Conference Wed, 06 Mar 2019 16:30:00 -0500 MeiraGTx News Releases 6921 MeiraGTx Announces $80 Million Private Placement of Ordinary Shares https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-announces-80-million-private-placement-ordinary-shares LONDON and NEW YORK , Feb. 27, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has agreed to sell approximately 5.8 million ordinary shares at a price of $13.80 per share. Wed, 27 Feb 2019 08:15:00 -0500 MeiraGTx News Releases 6881 MeiraGTx Appoints Martin Indyk, Ph.D. to Board of Directors https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-appoints-martin-indyk-phd-board-directors LONDON and NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Martin Indyk to its Board of Directors. Martin Indyk is an American diplomat who has served in senior Thu, 21 Feb 2019 16:30:00 -0500 MeiraGTx News Releases 6861 MeiraGTx to Present at the BIO CEO & Investor Conference https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-present-bio-ceo-investor-conference LONDON and NEW YORK, Feb. 05, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes , Ph.D., president and chief executive officer of MeiraGTx , will present at the BIO CEO & Investor Tue, 05 Feb 2019 08:30:00 -0500 MeiraGTx News Releases 6836